Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on biomarkers in early diabetic nephropathy in Japanese with type 2 diabetes

Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on biomarkers in early diabetic nephropathy in Japanese with type 2 diabetes - Nephropathy markers in type 2 diabetes with sodium-glucose co-transporter 2 (SGLT2) inhibitors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000021619

Enrollment

Registered

2016-03-31

Start date

2016-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes who fulfilled the following criteria. 1) Aged more than 20, less than 70 2) Patients whose baseline eGFR was >= 30ml/min/1.73m^2 3)Patients treated with diet, exercise or antidiabetic medications except SGLT2 inhibitor. 4) Having provided voluntary written consent for participation in this study.

Exclusion criteria

Exclusion criteria: Patients corresponding to any of the following are inapplicable 1) Patients with a history of allergy to any component of the study medications 2)Patients with severe complications( liver disease, mental disorder, cancer) 3)Patients with severe ketosis or diabetic coma. 4)Patients with severe infections, perioperative status, or severe trauma 5) Patients whose baseline eGFR were <29 ml/min/1.73m^2 6) Patients with kidney disease other than diabetic nephropathy.(Specifically, patients with occult blood positive) Patients with renal transplantations, or using drugs with nephrotoxic. 7)Pregnancy or lactation in women 8)Inadequacy of usingig this therapy

Design outcomes

Primary

Measure	Time frame
Change of urinary biomarkers (albumin excretion, L-FABP,NAG, beta 2 MG, type 4 collagen) from the baseline to the endpoint (after 1, 3 and 6 months) of SGLT2 inhibitors	—

Secondary

Measure	Time frame
Change of BMI, various metabolic disfunctions (hypertension, glucose metabolism, lipid profile, uric acid), and renal function after 1, 3 and 6 months of SGLT2 inhibitors	—

Countries

Japan

Contacts

Public ContactHiromi Konishi

Yokohama City University Graduate School of Medicine Department of Endocrinology and Metabolism

t146035b@yokohama-cu.ac.jp045-787-2639

Outcome results